CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 149-155

  Trietsch, Marjolijn D ^a   Spaans, Vivian M ^a   Ter Haar, Natalja T ^a   Osse, Elisabeth M ^a   Peters, Alexander A W ^a   Gaarenstroom, Katja N ^a   Fleuren, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CDKN2A; HRAS; Somatic mutation; Squamous cell carcinoma; Survival; Vulva

Indexed keywords

AGED; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CDKN2A(P16) GENE; CONTROLLED STUDY; CTNNB1 GENE; FBXW7 GENE; FEMALE; FGFR2 GENE; FGFR3 GENE; FOXL2 GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PAPILLOMAVIRUS INFECTION; PIK3CA GENE; PPP2R1A GENE; PREVALENCE; PTEN GENE; TP53 GENE; VULVA CARCINOMA; VULVAR SQUAMOUS CELL CARCINOMA; GENETICS; MORTALITY; MUTATION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VULVA TUMOR;

HRAS PROTEIN, HUMAN; P16 PROTEIN, HUMAN; PROTEIN P21; TUMOR PROTEIN;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P16; HUMANS; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; VULVAR NEOPLASMS;

EID: 84908044384     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.094     Document Type: Article

References (34)

1. P.L. Judson, E.B. Habermann, N.N. Baxter, S.B. Durham, and B.A. Virnig Trends in the incidence of invasive and in situ vulvar carcinoma Obstet Gynecol 107 2006 1018 1022
2. H.P. van de Nieuwenhof, L.F. Massuger, I.A. van der Avoort, R.L. Bekkers, M. Casparie, and W. Abma Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age Eur J Cancer 45 2009 851 856
3. J. van der Velden Surgical interventions for early squamous cell carcinoma of the vulva Cochrane Database of Systematic Reviews 2000 10.1002/14651858.CD002036 Issue 2. Art. No.: CD002036.
4. J.A. de Hullu, and A.G. van der Zee Surgery and radiotherapy in vulvar cancer Crit Rev Oncol Hematol 60 2006 38 58
5. K.N. Gaarenstroom, G.G. Kenter, J.B. Trimbos, I. Agous, F. Amant, and A.A. Peters Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions Int J Gynecol Cancer 13 2003 522 527
6. N.F. Hacker Vulvar cancer J.S. Berek, N.F. Hacker, Practical, gynecologic oncology 2005 543 576
7. I. van der Avoort, H. Shirango, B.M. Hoevenaars, J.M. Grefte, J.A. de Hullu, and P.C. de Wilde Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways Int J Gynecol Pathol 25 2006 22 29
8. H.P. van de Nieuwenhof, I.A. van der Avoort, and J.A. de Hullu Review of squamous premalignant vulvar lesions Crit Rev Oncol Hematol 68 2008 131 156
9. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 [%20]
10. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, and G. Fountzilas Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
11. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
12. L. Santarpia, Y. Qi, K. Stemke-Hale, B. Wang, E.J. Young, and D.J. Booser Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers Breast Cancer Res Treat 134 2012 333 343
13. S.A. Forbes, G. Bhamra, S. Bamford, E. Dawson, C. Kok, and J. Clements The Catalogue of Somatic Mutations in Cancer (COSMIC) Curr Protoc Hum Genet 2008 10.1002/0471142905.hg1011s57 [Chapter 10:Unit 10.11]
14. V.M. Spaans, M.D. Trietsch, S. Crobach, E. Stelloo, D. Kremer, and E.M. Osse Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers PLoS One 9 2014 e93451
15. W.T. Creasman New gynecologic cancer staging Gynecol Oncol 58 1995 157 158
16. S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynaecol Obstet 105 2009 103 104
17. A.G. van der Zee, M.H. Oonk, J.A. de Hullu, A.C. Ansink, I. Vergote, and R.H. Verheijen Sentinel node dissection is safe in the treatment of early-stage vulvar cancer J Clin Oncol 26 2008 884 889
18. M. Schrevel, A. Gorter, S.M. Kolkman-Uljee, J.B. Trimbos, G.J. Fleuren, and E.S. Jordanova Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer Mod Pathol 24 2011 720 728
19. G. Hennig, M. Gehrmann, U. Stropp, H. Brauch, P. Fritz, and M. Eichelbaum Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression Clin Chem 56 2010 1845 1853
20. C.F. Vermeulen, E.S. Jordanova, K. Szuhai, S. Kolkman-Uljee, M.A. Vrede, and A.A. Peters Physical status of multiple human papillomavirus genotypes in flow-sorted cervical cancer cells Cancer Genet Cytogenet 175 2007 132 137
21. D. Fumagalli, P.G. Gavin, Y. Taniyama, S.I. Kim, H.J. Choi, and S. Paik A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes BMC Cancer 10 2010 101
22. M.D. Trietsch, A.A. Peters, K.N. Gaarenstroom, S.H. van Koningsbrugge, N.T. ter Haar, and E.M. Osse Spindle cell morphology is related to poor prognosis in vulvar squamous cell carcinoma Br J Cancer 109 2013 2259 2265
23. M. Del Pino, L. Rodriguez-Carunchio, and J. Ordi Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma Histopathology 62 2013 161 175
24. N. Soufir, S. Queille, M. Liboutet, O. Thibaudeau, F. Bachelier, and G. Delestaing Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors Br J Dermatol 156 2007 448 453
25. A.H. Holway, K.M. Rieger-Christ, W.R. Miner, J.W. Cain, J.M. Dugan, and J.A. Pezza Somatic mutation of PTEN in vulvar cancer Clin Cancer Res 6 2000 3228 3235
26. J.E. Fata, S. Debnath, E.C. Jenkins Jr., and M.V. Fournier Nongenomic mechanisms of PTEN regulation Int J Cell Biol 2012 379685
27. L.Y. Huw, C. O'Brien, A. Pandita, S. Mohan, J.M. Spoerke, and S. Lu Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer Oncogenesis 2 2013 e83 10.1038/oncsis.2013.46.:e83
28. E. Castellano, and J. Downward RAS interaction with PI3K: more than just another effector pathway Genes Cancer 2 2011 261 274
29. J. Roper, M.J. Sinnamon, E.M. Coffee, P. Belmont, L. Keung, and L. Georgeon-Richard Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer Cancer Lett 347 2014 204 211
30. C. Romagosa, S. Simonetti, L. Lopez-Vicente, A. Mazo, M.E. Lleonart, and J. Castellvi p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors Oncogene 30 2011 2087 2097
31. A. Sigal, and V. Rotter Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome Cancer Res 60 2000 6788 6793
32. H. Mineta, A. Borg, M. Dictor, P. Wahlberg, J. Akervall, and J. Wennerberg p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma Br J Cancer 78 1998 1084 1090
33. S. Sjogren, M. Inganas, T. Norberg, A. Lindgren, H. Nordgren, and L. Holmberg The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry J Natl Cancer Inst 88 1996 173 182
34. Z. Zhang, R. Yao, J. Li, Y. Wang, C.W. Boone, and R.A. Lubet Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53 Mol Cancer Res 3 2005 563 574